Scholarlink

<p><b>Objective.</b> To study the relationship between markers of oxidative stress and depression in patients diagnosed with Parkinson’s disease, with an emphasis on the effects of therapy on biochemical parameters. <b>Materials and methods.</b> The study included 60 participants (26 women and 34 men, mean age 65.13 ± 0.84 years) who received fluvoxamine 100 mg/day as monotherapy (study group, <i>n</i> = 30) or as combination therapy (reference group, <i>n</i> = 30) consisting of the antioxidant drug Cytoflavin and fluvoxamine 100 mg/day. The control group consisted of 20 essentially healthy elderly subjects. Clinical, psychometric, and statistical investigation methods were used to study the dynamics of depressive symptoms and markers of oxidative stress in patients diagnosed with Parkinson’s disease during three-month courses of treatment with fluvoxamine and Cytoflavin. <b>Results.</b> Over the three months of treatment, the mean Hamilton Depression Rating Scale score decreased from 26.63 ± 0.33 to 7.22 ± 0.5 points (<i>p</i> ≤ 0.01) in the study group and from 26.51 ± 0.29 to 12.18 ± 1.1 points in the reference group. Mean HADS scores decreased from 15.46 ± 0.8 to 7.1 ± 0.1 points (<i>p</i> ≤ 0.05) in the study group and from 15.14 ± 0.8 to 9.7 ± 1.2 points in the reference group. After treatment, all patients showed significant slowing of lipid peroxidation processes, increases in the concentrations of antioxidant enzymes, and statistically significant (<i>p</i> &lt; 0.01) increases in the reduced glutathione concentration, with a more significant improvement in the study group. <b>Conclusions.</b> The results of the present comparative analysis of the effectiveness of the treatment of depression in patients with Parkinson’s disease showed that the combination of fluvoxamine and Cytoflavin provided a more marked therapeutic effect than fluvoxamine monotherapy. These findings highlight the need to integrate combined approaches in the development of new treatment strategies for depressive conditions based on personalized assessment of the clinical picture of depressive disorder and biomarkers of oxidative stress.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oxidative Stress and Depression in Parkinson’s Disease

  • 期刊论文

  • 发表日期：

    2026年3月18日

查看全文
  • S. A. Trofimova,
  • L. V. Lukina,
  • V. A. Mikhailov,
  • E. E. Dubinina

摘要

Objective. To study the relationship between markers of oxidative stress and depression in patients diagnosed with Parkinson’s disease, with an emphasis on the effects of therapy on biochemical parameters. Materials and methods. The study included 60 participants (26 women and 34 men, mean age 65.13 ± 0.84 years) who received fluvoxamine 100 mg/day as monotherapy (study group, n = 30) or as combination therapy (reference group, n = 30) consisting of the antioxidant drug Cytoflavin and fluvoxamine 100 mg/day. The control group consisted of 20 essentially healthy elderly subjects. Clinical, psychometric, and statistical investigation methods were used to study the dynamics of depressive symptoms and markers of oxidative stress in patients diagnosed with Parkinson’s disease during three-month courses of treatment with fluvoxamine and Cytoflavin. Results. Over the three months of treatment, the mean Hamilton Depression Rating Scale score decreased from 26.63 ± 0.33 to 7.22 ± 0.5 points (p ≤ 0.01) in the study group and from 26.51 ± 0.29 to 12.18 ± 1.1 points in the reference group. Mean HADS scores decreased from 15.46 ± 0.8 to 7.1 ± 0.1 points (p ≤ 0.05) in the study group and from 15.14 ± 0.8 to 9.7 ± 1.2 points in the reference group. After treatment, all patients showed significant slowing of lipid peroxidation processes, increases in the concentrations of antioxidant enzymes, and statistically significant (p < 0.01) increases in the reduced glutathione concentration, with a more significant improvement in the study group. Conclusions. The results of the present comparative analysis of the effectiveness of the treatment of depression in patients with Parkinson’s disease showed that the combination of fluvoxamine and Cytoflavin provided a more marked therapeutic effect than fluvoxamine monotherapy. These findings highlight the need to integrate combined approaches in the development of new treatment strategies for depressive conditions based on personalized assessment of the clinical picture of depressive disorder and biomarkers of oxidative stress.